Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Calyxt Advances Herbicide-Tolerant Wheat and Improved Oil Composition Canola Product Candidates to Phase 1

Calyxt,Inc.
Posted on: 03 Oct 17

Calyxt, Inc. (NASDAQ:CLXT), a consumer-centric, food- and agriculture-focused company, today announced that the Company’s herbicide-tolerant wheat, its third wheat product candidate, and improved oil composition canola, its first canola product candidate, have advanced to Phase 1. This latest milestone is reflective of Calyxt’s rapidly advancing product pipeline, powered by the Company’s proprietary gene editing technology TALEN®, as well as its deep expertise and innovation in the gene editing space.

“This advancement to Phase 1 for both of these product candidates marks yet another major step in Calyxt’s ongoing efforts to create healthier specialty food ingredients for consumers and agricultural productivity for farmers all over the country,” said Federico Tripodi, Calyxt CEO. “Canola and wheat represent major growth opportunities for the Company, and we look forward to continuing along the path of bringing these product candidates to market in a time- and cost-efficient manner.”

The herbicide-tolerant wheat candidate joins Calyxt’s high fiber and disease-resistant wheat pipeline and will provide another tool to help farmers manage weed resistance challenges to glyphosate and other herbicides. Additionally, Calyxt’s first canola product candidate will produce oil with an improved composition profile, all while retaining the same important characteristics of traditional canola oil.

With these phase advancements, Calyxt now has a total of nine product candidates in Phase 1 or higher across its five crops: soybeans, wheat, canola, potatoes and alfalfa.

About Calyxt

Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. By combining its leading gene-editing technology and technical expertise with its innovative commercial strategy, Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance, for farmers. Calyxt is located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market (ticker: CLXT).

For further information please visit our website: www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis Group.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in our registration statement on Form S-1, along with our other filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170925006426/en/

Business Wire
www.businesswire.com

Last updated on: 03/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.